Non-alcoholic steatohepatitis (NASH) is a growing health concern that affects millions of patients worldwide. It is liver cell inflammation and death associated with a buildup of fat within the liver – liver fat that is not the result of excessive alcohol intake. Liver cell injury and death are followed by fibrosis (scar tissue) development. Approximately 5 percent of the general US adult population has NASH, and it is estimated that NASH will be the primary reason for liver transplantation among men, as well as women, by the year 2020.
The staggering public health implications of this disease have fueled research and investment toward diagnostics and treatments, but many hurdles remain. In this free webinar, a panel of speakers will explore the challenges to successfully bring effective therapies to market and how we might overcome them.